Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS (REFALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03505021
Recruitment Status : Active, not recruiting
First Posted : April 20, 2018
Last Update Posted : August 30, 2019
Sponsor:
Information provided by (Responsible Party):
Orion Corporation, Orion Pharma

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : August 30, 2020
Estimated Study Completion Date : October 30, 2020